200 JCI hospitals put Saudi Arabia and UAE in GCC contest for cardiac patients

Saudi Arabia is adding pressure to a GCC medical tourism market where more than 200 Joint Commission International (JCI)-accredited hospitals now compete for international cardiac patients.

The Travel And Tour World report, published on 20 June 2026, places Saudi Arabia alongside the UAE, Qatar, Bahrain, Kuwait and Oman as the bloc uses hospital accreditation, airline access and shorter waiting lists to attract medical travellers. For UAE operators, the commercial risk is clear: Dubai and Abu Dhabi have built medical travel channels over years, while Saudi hospital groups now have capital, domestic procedure volume and government backing to pursue the same cardiac and complex surgery patients.

What UAE operators should watch

The UAE is already a measurable medical tourism market. Dubai attracted 691,478 medical tourists in 2023, with healthcare spending above AED 1.034 billion, according to a Government of Dubai Media Office release citing the Dubai Health Authority (DHA). That compared with 674,000 medical tourists and AED 992 million in 2022.

The Saudi move changes the sales test for UAE providers. A patient comparing Riyadh, Dubai and Abu Dhabi will look at waiting time, outcome data, physician reputation, bundled pricing and travel support. Cardiovascular care is the category to watch because it combines high acuity with high ticket values. A hospital that cannot show procedure volumes, complication rates and post-discharge coordination has less room to rely on brand.

• CEOs should map Saudi competitors by specialty, payer source and referral market before approving international patient targets.
• CFOs should test bundled cardiac and orthopaedic packages against Saudi pricing, including diagnostics, ICU days and companion services.
• COOs should audit discharge summaries, interpreter coverage and complaint handling for medical travel cases.
• CMOs should separate wellness demand from complex-care demand in campaign reporting.

Regulatory burden is part of the product

In Dubai, DHA regulates licensed facilities that market medical services to visitors. In Abu Dhabi and Al Ain, the relevant regulator is the Department of Health - Abu Dhabi (DOH). In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, operators must account for the Ministry of Health and Prevention (MOHAP). That split matters because a regional marketing claim can become an operational risk if the licence, package terms or patient pathway do not match the emirate of care.

Abu Dhabi's medical tourism standard is more prescriptive than a marketing checklist. The DOH standard says a Medical Tourism Network member must be licensed in the emirate, hold AAMEN certification, integrate its electronic medical record with Malaffi, maintain at least 3 Diamonds under Muashir where applicable, and obtain recognised medical travel accreditation such as TEMOS, ISO 22525 or Global Healthcare Accreditation within 18 months of the standard's effective date.

“We look forward to advancing our mission to continuously improve safety and quality of care.” Jean Courtney, interim president and chief executive officer, Joint Commission International.

Saudi scale raises the bar on evidence

JCI opened a Riyadh office in 2023 after more than 20 years serving the Middle East, according to Hospitals Magazine. The same report said JCI accredited more than 400 healthcare organisations in the Middle East and Africa, with 27% located in Saudi Arabia. That gives Saudi providers a quality marker recognised by insurers, facilitators and international referral agents.

UAE hospitals still have advantages: Dubai has airport scale, a mature private hospital base and DHA-backed health tourism reporting. Abu Dhabi has tertiary assets, Malaffi connectivity and a formal DOH medical tourism framework. The gap is proof. Operators that publish specialty-level outcomes, package exclusions, expected waiting times and follow-up protocols will be easier for overseas patients and referring physicians to assess.

By 2027, UAE groups should expect higher international patient acquisition costs in cardiac surgery, orthopaedics, fertility, oncology diagnostics and executive health checks. The number to remember is 200-plus JCI-accredited GCC hospitals. Providers with regulator-clean pathways and auditable outcomes will have the stronger case when facilitators compare six GCC markets on price, speed and clinical risk.